Head-To-Head Contrast: Bicara Therapeutics (NASDAQ:BCAX) & Lipella Pharmaceuticals (NASDAQ:LIPO)

Lipella Pharmaceuticals (NASDAQ:LIPO) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Profitability

This table compares Lipella Pharmaceuticals and Bicara Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lipella Pharmaceuticals	-882.82%	-192.33%	-154.24%
Bicara Therapeutics	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations for Lipella Pharmaceuticals and Bicara Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipella Pharmaceuticals	0	0	1	0	3.00
Bicara Therapeutics	0	0	6	1	3.14

Lipella Pharmaceuticals currently has a consensus price target of $16.00, suggesting a potential upside of 461.40%. Bicara Therapeutics has a consensus price target of $43.00, suggesting a potential upside of 255.08%. Given Lipella Pharmaceuticals’ higher probable upside, analysts plainly believe Lipella Pharmaceuticals is more favorable than Bicara Therapeutics.

Valuation & Earnings

This table compares Lipella Pharmaceuticals and Bicara Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipella Pharmaceuticals	$483,533.00	7.13	-$4.62 million	($4.25)	-0.67
Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A

Bicara Therapeutics has lower revenue, but higher earnings than Lipella Pharmaceuticals.

Insider & Institutional Ownership

74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Bicara Therapeutics beats Lipella Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

About Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

About Bicara Therapeutics

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.